The present disclosure provides methods for treating, preventing or reducingthe severity of an eye disease. The methodsof the present disclosure comprise administering to a subject in need thereofa therapeutic composition comprising an APLNR antagonistsuch as an anti-APLNR antibody in combination with a vascular endothelialgrowth factor (VEGF) antagonist (for example, aflibercept).